Read more
Informationen zum Autor Karen Bush is the editor of Antimicrobial Therapeutics Reviews: Antibiotics that Target the Ribosome, Volume 1241, published by Wiley. Klappentext "This second installment of Antimicrobial Therapeutics Reviews presents scholarly reviews on several key areas in the field of antimicrobial therapeutics, including several papers on issues relating to antibiotics that target the ribosome. Topics covered include plasmid-encoded resistance determinants for agents that bind the ribosome, new compound classes targeting the ribosome, sequence-specific action of antibiotics binding the ribosome, smFRET approaches to determine MOA of antibiotics binding to the ribosome, new approaches for treating Staphylococcus biofilm infections, and the history of tetracyclins. The volume also features reviews dealing with drug development, such as pleuromutilin discovery and development challenges and an update on newer oxazolidinones such as torezolid and radezolid, and a review on regulatory hurdles for new antibiotics"-- Zusammenfassung This second installment of Antimicrobial Therapeutics Reviews presents scholarly reviews on several key areas in the field of antimicrobial therapeutics! including several papers on issues relating to antibiotics that target the ribosome. Inhaltsverzeichnis Introduction to Antimicrobial therapeutics reviews : antibiotics that target the ribosome On the specificity of antibiotics targeting the large ribosomal subunit The history of the tetracyclines Macrolide antibiotics in the ribosome exit tunnel : species-specific binding and action The oxazolidinones : past, present, and future Are pleuromutilin antibiotics finally fit for human use? Plasmid-mediated resistance to protein biosynthesis inhibitors in staphylococci New approaches for treating staphylococcal biofilm infections Antibiotics in development targeting protein synthesis Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world Aureomycin : a product of the continuing search for new antibiotics ...
